Concepedia

Youngseon Byeon

YB

Statistics

Publications

5

Citations

93

H-Index

5

Active since

2021

Affiliations

Yonsei University(Current)

Jeuk (South Korea)

Seoul National University

Youngseon Byeon is an author at Yonsei University specializing in oncology, cancer immunotherapy, and immune checkpoint inhibitor therapy.

Publications per year

2021–2024

5

Publications

5

Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches

Ji Eun Won, Youngseon Byeon, Tae In Wi et al. · Journal for ImmunoTherapy of Cancer · 2022 · 37 citations · Full text

Pharmacy, Immunology, Oncology +17

Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor

Chun‐Bong Synn, Dong Kwon Kim, Jae Hwan Kim et al. · Yonsei Medical Journal · 2021 · 18 citations · Full text

Medicine, Immunology, Oncology +17

SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models

Chun‐Bong Synn, Sung Eun Kim, Hee Kyu Lee et al. · Clinical & Translational Immunology · 2021 · 14 citations · Full text

Medicine, Oncology, Pharmacology +17

CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production

Kwangmin Na, Seul Lee, Dong Kwon Kim et al. · Frontiers in Immunology · 2024 · 14 citations · Full text

Life Sciences, Immunology, Oncology +17

Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity

Wongeun Lee, Dong Kwon Kim, Chun‐Bong Synn et al. · Frontiers in Oncology · 2022 · 10 citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 5